Fabhalta (iptacopan) and Empaveli (pegcetacoplan), two approved treatments for C3 glomerulopathy (C3G), cause different changes in blood proteins that may help doctors monitor treatment effects, a U.S. study found. While both treatments…
Fabhalta (iptacopan) and Empaveli (pegcetacoplan), two approved treatments for C3 glomerulopathy (C3G), cause different changes in blood proteins that may help doctors monitor treatment effects, a U.S. study found. While both treatments…
One04 Therapeutics’ first-in-class experimental therapy CPV-104 showed early signs of reducing protein in the urine in people with C3 glomerulopathy (C3G), while kidney function remained stable, according to interim data from an early-stage…
The approved therapy Fabhalta (iptacopan) is effective at reducing urine protein content for most people with hard-to-treat C3 glomerulopathy (C3G), a real-world study showed. Although Fabhalta was effective for most patients, the researchers…
Get regular updates to your inbox.
Don't have an account?
|
Already have an account?
Create your account by filling in the information below:
By creating an account, you are agreeing to the Privacy Policy and Terms of Service.